Welcome to our dedicated page for MARAVAI LIFESCIENCES HOLDINGS SEC filings (Ticker: MRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Maravai LifeSciences Holdings, Inc. filings document the formal disclosures of a Nasdaq-listed life sciences operating company with Class A common stock. Form 8-K reports furnish quarterly and annual financial results, including revenue, net loss, adjusted EBITDA and business updates for the TriLink nucleic acid synthesis and Cygnus biologics safety testing operations.
The company’s proxy materials describe annual meeting matters, director elections, independent auditor ratification, executive compensation votes and board governance. Other current reports record leadership succession, board-size and committee changes, equity-award treatment, and restructuring actions classified as exit or disposal activities, including related cost disclosures and risk language.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) disclosed that Chief Executive Officer and director Bernd Brust had 29,250 shares of Class A Common Stock withheld on September 8, 2026 to pay tax liabilities arising from the vesting of restricted stock unit awards, at a value of $7.32 per share. After this tax-withholding event, he held 1,561,249 Class A shares directly and 466,771 Class A shares indirectly through The Bernd Brust Management Trust. No transactions were reported under a Rule 10b5-1 trading plan.
For MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), Chief Financial Officer Rajesh Asarpota reported a Form 4 transaction involving 5,465 shares of Class A Common Stock on 2026-08-31. These shares were withheld to satisfy tax withholding obligations upon vesting of restricted stock units, not an open-market trade. After this tax-withholding transaction, Asarpota directly holds 423,486 shares of Class A Common Stock.
Maravai LifeSciences Holdings, Inc. Class A common stock is reported as being beneficially owned in aggregate by a group led by Hudson View Holdings LLC and related entities and individuals. The group reports beneficial ownership of 4,009,250 shares of Class A common stock, representing 2.72% of the class as of June 30, 2026.
The group members are Hudson View Holdings LLC, Hudson View Capital LLC, JD Squared Holdings II LLC, JD Squared Capital II LLC, Stuart Feldman, Matthew Barkoff and Joshua Wool. All reported voting and dispositive powers are sole, with no shared voting or dispositive power disclosed, and the group states that it owns 5 percent or less of the class.
MARAVAI LIFESCIENCES HOLDINGS, INC. director and Chief Executive Officer Bernd Brust reported a transaction involving 29,250 shares of Class A Common Stock on 2026-08-10. These shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock unit awards, at a reference value of $6.23 per share. Following this tax-withholding disposition, Brust directly holds 1,590,499 Class A shares and has an additional 466,771 Class A shares held indirectly through The Bernd Brust Management Trust.
Maravai LifeSciences reported improved results for the quarter and six months ended June 30, 2026. Revenue reached $51,442 thousand in Q2 and $117,279 thousand year‑to‑date, led by TriLink growth. Gross margin rose to 40.1% in Q2 and 46.3% for the first half.
The company still recorded a net loss attributable to Maravai of $12,416 thousand in Q2 and $16,149 thousand year‑to‑date, but Adjusted EBITDA turned positive at $8,674 thousand for Q2 and $29,001 thousand for the first half. Operating cash flow improved to an inflow of $12,657 thousand, while cash and restricted cash declined to $70,581 thousand after refinancing into a new $150.0 million term loan maturing in 2032. Management does not expect further high‑volume CleanCap® revenue from commercial COVID‑19 vaccine programs in 2026.
Maravai LifeSciences Holdings, Inc. reported second quarter 2026 revenue of $51.4 million, up 8.5% year over year, with TriLink growing 11.5% and Cygnus up 2.8%. Net loss narrowed to $(21.6) million from $(69.8) million, and Adjusted EBITDA improved to $8.7 million from $(10.4) million.
For the six months ended June 30, 2026, total revenue increased 24.4%, driven by TriLink’s 37.3% growth, including $14.3 million of high‑volume CleanCap orders, while Cygnus grew 2.1%. Six‑month net loss was $(28.0) million versus $(122.7) million, and Adjusted EBITDA rose to $29.0 million from $(21.0) million.
The company reiterated full‑year 2026 revenue guidance of $205.0–$215.0 million and raised Adjusted EBITDA guidance to $33.0–$35.0 million from $30.0–$32.0 million. Management highlighted a new GMP enzyme manufacturing facility and continued adoption of the ModTail™ product line, now with more than 125 active customers.
Maravai Lifesciences Holdings, Inc. reported that Chief Financial Officer Rajesh Asarpota had 5,465 shares of Class A Common Stock withheld on July 30, 2026, at $6.59 per share to satisfy tax withholding obligations related to the vesting of restricted stock unit awards. After this tax-withholding disposition, he directly holds 428,951 shares. The transaction was not reported as made pursuant to a Rule 10b5-1 trading plan.
MARAVAI LIFESCIENCES HOLDINGS, INC. Chief Executive Officer Bernd Brust reported routine equity compensation-related activity in Class A Common Stock. A total of 29,250 shares were withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards, a non-open-market, tax-related disposition. Following these transactions, Brust holds 1,619,749 Class A shares directly and 466,771 Class A shares indirectly through The Bernd Brust Management Trust.
Maravai Lifesciences Holdings Chief Financial Officer Rajesh Asarpota reported a routine share disposition related to equity compensation. On the vesting of restricted stock unit awards, 65,584 shares of Class A Common Stock were withheld at $6.39 per share to satisfy tax withholding obligations, rather than being sold on the open market. After this tax withholding event, Asarpota directly holds 434,416 shares of Maravai Lifesciences Class A Common Stock.
Maravai LifeSciences Holdings, Inc. Schedule 13G shows that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported acquiring beneficial ownership of more than 5% of the Class A common stock on 06/23/2026, and state they ceased to be beneficial owners of more than 5% by the date of this filing. The cover data lists 6,900,258 shares associated with shared voting and dispositive power, representing 4.7% of the class as reported on the cover pages. A Joint Filing Agreement dated 06/26/2026 is attached and the filing is signed by Gil Raviv and Israel A. Englander.